Adding baricitinib to standard-of-care topical corticosteroids significantly improved disease severity, they said. Baricitinib is approved for the treatment of adults with moderately to severely active rheumatoid arthritis in more than 60 countries.
Price: 81.91, Change: -3.65, Percent Change: -4.27
|Energy Transfer Q4 Results Top Street Views|
|Life Storage Q4 Results Top Street View|
|Tenaris S.A Q4 Sales Just Miss, Earnings Drop Vs Yr ...|
|Insider Trends: Dana Insider Converts Option/Derivat...|
|Insider Trends: Equifax Insider Makes Tax Sale Inter...|